Finisterre

Finister contains the component finasteride, which is an artificial 4-azosteroid compound. It specifically slows down the action of testosterone-5-α-reductase type 2 (an intracellular enzyme of the prostate that transforms testosterone into a more active androgen called dihydrotestosterone).

The therapy contributes to a significant reduction in the total number of urological signs associated with prostate hyperplasia, achieving a stable regression of prostate size along with an increase in the maximum urine flow rate and improvement of clinical manifestations. In the case of continuous use, clinically noticeable effects are noted after 3 months.

Indications Finisterre

It is used for benign prostatic hyperplasia to achieve the following effects:

• reduction in the size of the enlarged prostate, relief of symptoms caused by adenoma, and improvement of urinary outflow;
• reducing the likelihood of acute urinary retention and the need for surgery (prostatectomy and transurethral resection of the prostate).

Release form

The drug is produced in the form of tablets, in the amount of 14 pieces in a cell pack; there are 2 such packs in a box.

Pharmacodynamics

By slowing down the transformation of testosterone into the element dihydrotestosterone, the drug effectively reduces the levels of this hormone in the blood and prostate tissue (within 24 hours from the moment of application). This causes a decrease in the size of the prostate and a weakening of the dysuric symptoms associated with hypertrophy.

The drug is synthesized with androgen endings and has no effect on the hypothalamus-pituitary structure.

[ 1 ], [ 2 ]

Pharmacokinetics

When administered orally, the bioavailability level is approximately 63%. Intraplasmic Cmax values are observed after 1-2 hours from the moment of administration; this indicator is on average 37 ng/l. Approximately 90% of finasteride is synthesized in blood plasma with protein.

The total clearance values are approximately 165 ml per minute, and the distribution volume is 76 liters. The drug can overcome the BBB, but its level in the cerebrospinal fluid does not reach significant volumes. In the case of using the drug in a dose of 5 mg per day, the finasteride indicator in the sperm will be 0-20 ng / l.

The half-life is 6 hours. About 40% is excreted as metabolic elements through the kidneys, and another 60% through the intestines. In the urine, the metabolic component with the monocarboxyl group is mainly recorded.

In case of repeated use, a slow accumulation of the drug in the body occurs: after the administration of the drug for 17 days in a dose of 5 mg per day, the indicator in the blood plasma is approximately 50% higher than the values observed with a single dose.

After oral administration, the medication effectively reduces the dihydrotestosterone level in blood plasma and prostate tissues within the first day. But to obtain the necessary clinical result, the medication must be used for several months.

After daily oral administration of the drug in a dose of 5 mg per day, the plasma level is 8-10 ng/ml, remaining within these limits for a long period of time.

In elderly men, the rate of excretion of finasteride decreases slightly. In people over 70 years of age, the half-life of the drug is approximately 8 hours, and in people aged 18-60 years - 6 hours. But this factor is not a contraindication for the use of the drug in the elderly.

[ 3 ]

Dosing and administration

The medicine is taken orally - 1 tablet of 5 mg once a day. It should be taken with food (but can also be taken without it), without chewing the tablet. The duration of the treatment cycle is individually selected by the doctor.

[ 7 ], [ 8 ]

Use Finisterre during pregnancy

The drug is not used to treat women.

Women of childbearing age and pregnant women should not come into contact with crushed or damaged tablets of the drug. Due to the ability of substances that inhibit the activity of 5-α-reductase type 2 to slow down the conversion of testosterone into the component dihydrotestosterone, such drugs, including Finister, can lead to problems in the development of the genitals of a male fetus. If the drug penetrates into the body of a pregnant woman, there is a risk of developing a negative effect on the formation and development of the fetus.

There is no information on the amount of finasteride absorbed into the body if it comes into contact with a broken tablet or the ejaculate of a man taking the drug. Women who are planning to conceive or are already pregnant should avoid such contact to eliminate the risk of harm to the fetus.

When breastfeeding, the above recommendations should be followed. There is no data on whether finasteride is excreted in breast milk. A nursing woman should use condoms when in contact with a man taking the medication.

Contraindications

Main contraindications:

• severe intolerance associated with the active ingredient or other components of the drug;
• uropathy of an obstructive form.

[ 4 ], [ 5 ], [ 6 ]

Side effects Finisterre

Finister is tolerated by patients without complications. Only occasionally do the following side effects appear:

• manifestations associated with reproductive function: sexual dysfunction (the frequency of these problems decreases during therapy), pain affecting the testicles, impotence, decreased libido, decreased ejaculate volume, ejaculation disorder, as well as enlargement of the mammary glands and their engorgement;
• Allergy symptoms: signs of severe intolerance, including hives, itching, rashes and swelling of the face and lips.

Storage conditions

Finistere should be stored in a place out of reach of children. Temperature indicators – no more than 25°C.

Shelf life

Finister can be used within a 36-month period from the date of manufacture of the medicinal product.

Application for children

The drug is not used in pediatrics because there is no data regarding medicinal efficacy and safety for children.

[ 9 ]

Analogues

Analogues of the drug are Finpros, Avodart, Proscar with Adenosteride, Finasteride and Penester with Finast, and in addition Prosteride and Prostan.